DTC

Five things for pharma marketers to know: Tuesday, August 29, 2017

Five things for pharma marketers to know: Tuesday, August 29, 2017

By

Drug ads make up to 38% of prime time commercials; Merck considers whether to pursue FDA approval for anacetrapib; BMS and Daiichi partner

Five things for pharma marketers to know: Tuesday, August 8, 2017

Five things for pharma marketers to know: Tuesday, August 8, 2017

By

A shorter list of risks in TV ads helps consumer comprehension; medical-school choice affects prescribing patterns; reps often show docs the same info

How Do Docs Learn About New Drugs? TV, Of Course

How Do Docs Learn About New Drugs? TV, Of Course

If asked, some will equivocate and say they get their facts from medical journals and from published studies, but never from those pesky misleading ads.

AMA votes to require disclosure of drug prices in DTC ads

AMA votes to require disclosure of drug prices in DTC ads

By

The association also recommended that the Centers for Medicare and Medicaid Services negotiate drug prices.

Physicians call for DTC ads to include retail prices

Physicians call for DTC ads to include retail prices

By

They are asking the American Medical Association to support the policy proposal.

The FDA cites risk info in letter over Contrave DTC ad

The FDA cites risk info in letter over Contrave DTC ad

By

The regulator also took issue with how Orexigen Therapeutics presented the risk information

What doctors have to say about those DTC ads

What doctors have to say about those DTC ads

By

We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It's not pretty.

The DTC Ads of 2016 That Shouldn't Have Happened

The DTC Ads of 2016 That Shouldn't Have Happened

By

Pharma marketers are producing plenty of exceptional creative work in the DTC realm. There are also plenty that prompt quick checks to make sure that one hasn't inadvertently clicked over to The Onion.

The Top 10 DTC Ads of 2016

The Top 10 DTC Ads of 2016

Mary Skoyles finds that DTC ads are getting better. "There's a lot of interesting work being done," she says. "There are more chances being taken."

The 2017 DTC Report: All the data in one place

The 2017 DTC Report: All the data in one place

Drugmakers again spent more on DTC advertising in 2016 than the year before.

Drugmakers again boost DTC spending, to $5.6 billion in 2016

Drugmakers again boost DTC spending, to $5.6 billion in 2016

By

Pfizer and Bristol-Myers Squibb were the top spenders last year.

Five things for pharma marketers to know: Monday, February 27, 2017

Five things for pharma marketers to know: Monday, February 27, 2017

By

Pfizer receives subpoena over patient assistance programs; drugmakers raise prices less this January than last; lawmakers have new plan to repeal ACA

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

By

Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.

Allergan to boost investment in DTC for Kybella

Allergan to boost investment in DTC for Kybella

By

Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.

Will he or won't he? Pharma speculates on President-elect Trump

Will he or won't he? Pharma speculates on President-elect Trump

By

If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.

Drugmakers spar with FDA over proposed DTC animation study

Drugmakers spar with FDA over proposed DTC animation study

By

The FDA responded to criticism from industry about its proposed research of DTC animation.

Pro ad report: All the data on journal spending in 1H 2016

Pro ad report: All the data on journal spending in 1H 2016

By

Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.

7 ways Viagra changed how drugs are marketed

7 ways Viagra changed how drugs are marketed

By

The inside story on a campaign for the ages, as told by the individuals who worked on it.

30 years later, DTC's complicated past still hasn't deterred marketers

30 years later, DTC's complicated past still hasn't deterred marketers

By

Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.

How the FDA Advanced DTC Advertising

How the FDA Advanced DTC Advertising

Five decades ago, pharmaceuticals were the protected province of health professionals. Today we have DTC ads, the internet, and pharmacy handouts.

Five things for pharma marketers to know: Wednesday, September 14, 2016

Five things for pharma marketers to know: Wednesday, September 14, 2016

By

Patients who ask for a prescription after seeing an ad are more likely to get one; Mylan's executive pay is now under scrutiny

Five things for pharma marketers to know: Monday, September 12, 2016

Five things for pharma marketers to know: Monday, September 12, 2016

By

Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes

MM&M's top 5 stories in August 2016

MM&M's top 5 stories in August 2016

By

Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck's Keytruda takes the lead in first-line cancer

DTC ads for Opdivo face further backlash

DTC ads for Opdivo face further backlash

By

Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.

Five things for pharma marketers to know: Wednesday, August 10, 2016

Five things for pharma marketers to know: Wednesday, August 10, 2016

By

A new bill exempting CME reporting gains physician support; NYT op-ed calls Opdivo DTC ad "misleading;" Valeant to sell non-core assets worth $8 billion

Five things for pharma marketers to know: Tuesday, June 14, 2016

Five things for pharma marketers to know: Tuesday, June 14, 2016

By

Physicians debate DTC tax write-off; Novo Nordisk's Victoza shows 13% benefit in reducing cardiovascular risks; Shire to acquire Pfizer bowel drug

Industry criticizes FDA's proposed DTC studies

Industry criticizes FDA's proposed DTC studies

By

Pharma companies took issue with the methodology for the FDA's proposed studies of advertising tactics.

Five things for pharma marketers to know: Monday, May 16, 2016

Five things for pharma marketers to know: Monday, May 16, 2016

By

Pfizer buys Anacor; Harvard Medical School loosens rules for faculty ties to pharma; Vermont poised to pass price transparency bill

Lobbyists argue DTC ad tax deduction may be a casualty of reform

Lobbyists argue DTC ad tax deduction may be a casualty of reform

By

Advertising lobbyist said eliminating the DTC ad tax deduction is a real threat to the industry.

Novartis launches DTC campaign for Entresto

Novartis launches DTC campaign for Entresto

By

The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.